{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:20:33Z","timestamp":1793780433288,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.esmoop.2024.103727","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:41:17Z","timestamp":1727282477000},"page":"103727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-0487","authenticated-orcid":false,"given":"J.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-6508","authenticated-orcid":false,"given":"M.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-763X","authenticated-orcid":false,"given":"Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0635-0786","authenticated-orcid":false,"given":"S.","family":"Leaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.103727_bib1","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2024.103727_bib2","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American Society of Clinical Oncology Clinical Practice Guideline Update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"7010","key":"10.1016\/j.esmoop.2024.103727_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","volume":"311","year":"1995","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.esmoop.2024.103727_bib4","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10183","key":"10.1016\/j.esmoop.2024.103727_bib5","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103727_bib6","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103727_bib7","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10274","key":"10.1016\/j.esmoop.2024.103727_bib8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103727_bib9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2024.103727_bib10","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 11","key":"10.1016\/j.esmoop.2024.103727_bib11","doi-asserted-by":"crossref","first-page":"XI67","DOI":"10.1093\/annonc\/mdz453.004","article-title":"Nivolumab (NIVO)\u00a0+ platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis","volume":"30","author":"Paz-Ares","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103727_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103727_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100273","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"issue":"S5","key":"10.1016\/j.esmoop.2024.103727_bib14","article-title":"LBA51 EMPOWER-Lung 3: cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)","volume":"32","author":"Gogishvili","year":"2021","journal-title":"Ann Oncol"},{"issue":"10S","key":"10.1016\/j.esmoop.2024.103727_bib15","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/j.jtho.2021.08.029","article-title":"Durvalumab \u00b1 tremelimumab\u00a0+ chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study","volume":"16","author":"Johnson","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103727_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103727_bib17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103727_bib18","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A\u00a0randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"0","key":"10.1016\/j.esmoop.2024.103727_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2024.103727_bib20","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1538-7445.AM2019-2383","article-title":"Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab","volume":"79","author":"Feng","year":"2019","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103727_bib21","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/2211-5463.13102","article-title":"Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage","volume":"11","author":"Hong","year":"2021","journal-title":"FEBS Open Bio"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103727_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103727_bib23","article-title":"Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors","volume":"8","author":"Desai","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103727_bib24","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2024.103727_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2020.06.007","article-title":"A\u00a0phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients","volume":"147","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103727_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103727_bib27","series-title":"AJCC Cancer Staging Manual","year":"2010"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103727_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0272989X13520192","article-title":"Adjusting survival time estimates to account for treatment switching in randomized controlled trials \u2013 an economic evaluation context: methods, limitations, and recommendations","volume":"34","author":"Latimer","year":"2014","journal-title":"Med Decis Making"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103727_bib29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103727_bib30","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1158\/1078-0432.CCR-12-2935","article-title":"The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement","volume":"19","author":"Villaruz","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103727_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103727_bib32","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/JTO.0b013e3182199c03","article-title":"Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials","volume":"6","author":"Soo","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103727_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/PPO.0000000000000058","article-title":"Survival disparities in non-small cell lung cancer by race, ethnicity, and socioeconomic status","volume":"20","author":"Tannenbaum","year":"2014","journal-title":"Cancer J"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103727_bib34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/JTO.0b013e3181e2f607","volume":"5","author":"Kawaguchi","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103727_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/JTO.0b013e3181b27b15","article-title":"Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status","volume":"4","author":"Ou","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103727_bib36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.21037\/tlcr-20-246","article-title":"A\u00a0meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians","volume":"9","author":"Peng","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103727_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e20690","article-title":"FDA analysis of outcomes in Asian patients (pts) with metastatic non-small cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors (ICI)","volume":"37","author":"Chang","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T19:06:18Z","timestamp":1729796778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2059702924014972"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103727","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103727"}}